| dbo:abstract |
CX-546 is an ampakine drug developed by Cortex Pharmaceuticals. It has been proposed as a treatment for schizophrenia. CX-546 was the second drug of note to come out of the Cortex research program, after CX-516, but while it was an improvement over its predecessor in some respects, it still has problems with limited oral bioavailability. However, CX-546 still represented a significant advance that led on to the development of newer compounds such as CX-614 and CX-717 with superior properties over the earlier drugs. CX-546 itself has been investigated for other applications, and most notably has been found to show significant efficacy in reversing the respiratory depression produced by sedative drugs such as opioids and barbiturates. No effective respiratory stimulants are currently marketed for this application, with CX-546 being only the third drug discovered (after BIMU-8 and BW373U86) that effectively relieves the respiratory depression induced by fentanyl without reducing the analgesic effects. CX-546 could be developed for this purpose, although it is more likely that Cortex will use newer and more potent analogues such as CX-1739 or CX-1763, which are likely to be more suitable for commercial development. (en) CX-546 es un fármaco ampakina desarrollado por Cortex Pharmaceuticals, que ha sido propuesto como tratamiento para la esquizofrenia. El CX-546 era el segundo fármaco por salir de la lista del programa de investigación de Cortex, después del CX-516, sin embargo, aunque poseía mejoras respecto a su predecesora en algunos aspectos, todavía tenía problemas con su capacidad limitada de biodisponibilidad oral. A pesar de ello, CX-546 aún representaba un avance significativo que condujo a la elaboración de nuevos compuestos tales como el y con varias propiedades superiores sobre los fármacos anteriores. CX-546 se ha investigado para otras aplicaciones, encontrándose sobre todo una eficacia significativa para la reversión de la producida por medicamentos sedantes tales como los opioides y barbitúricos. (es) CX-546 est un médicament ampakine développé par Cortex Pharmaceutique. (fr) |
| dbo:casNumber |
215923-54-9 |
| dbo:fdaUniiCode |
PV6YEC8983 |
| dbo:pubchem |
2890 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/CX546.png?width=300 |
| dbo:wikiPageID |
13839587 (xsd:integer) |
| dbo:wikiPageLength |
3956 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1085350530 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Ampakine dbc:Ampakines dbr:Schizophrenia dbc:Experimental_drugs dbc:Piperidines dbr:BW373U86 dbr:Barbiturates dbr:CX-516 dbr:Cortex_Pharmaceuticals dbc:Benzamides dbr:Fentanyl dbr:AMPA_receptor_positive_allosteric_modulator dbc:AMPA_receptor_positive_allosteric_modulators dbc:Benzodioxans dbc:Respiratory_agents dbr:Bioavailability dbr:Opioid dbr:BIMU-8 dbr:Respiratory_depression dbr:CX-1739 dbr:CX-614 dbr:CX-717 |
| dbp:c |
14 (xsd:integer) |
| dbp:casNumber |
215923 (xsd:integer) |
| dbp:chemspiderid |
2787 (xsd:integer) |
| dbp:h |
17 (xsd:integer) |
| dbp:iupacName |
23 (xsd:integer) |
| dbp:iupharLigand |
4166 (xsd:integer) |
| dbp:legalUs |
Investigational New Drug (en) |
| dbp:n |
1 (xsd:integer) |
| dbp:o |
3 (xsd:integer) |
| dbp:pubchem |
2890 (xsd:integer) |
| dbp:smiles |
C1CCNCC2=CC3=COCCO3 (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
LJUNPHMOGNFFOS-UHFFFAOYSA-N (en) |
| dbp:synonyms |
CX-546 (en) |
| dbp:unii |
PV6YEC8983 (en) |
| dbp:verifiedfields |
changed (en) |
| dbp:verifiedrevid |
443493909 (xsd:integer) |
| dbp:width |
180 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Respiratory-system-drug-stub dbt:Citation_needed dbt:Drugbox dbt:Ionotropic_glutamate_receptor_modulators dbt:Nervous-system-drug-stub dbt:Short_description dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Stdinchicite dbt:Other_respiratory_system_products |
| dcterms:subject |
dbc:Ampakines dbc:Experimental_drugs dbc:Piperidines dbc:Benzamides dbc:AMPA_receptor_positive_allosteric_modulators dbc:Benzodioxans dbc:Respiratory_agents |
| gold:hypernym |
dbr:Drug |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:Agent109190918 yago:CausalAgent100007347 yago:PhysicalEntity100001930 dbo:Drug yago:WikicatRespiratoryAgents umbel-rc:DrugProduct |
| rdfs:comment |
CX-546 est un médicament ampakine développé par Cortex Pharmaceutique. (fr) CX-546 is an ampakine drug developed by Cortex Pharmaceuticals. It has been proposed as a treatment for schizophrenia. CX-546 was the second drug of note to come out of the Cortex research program, after CX-516, but while it was an improvement over its predecessor in some respects, it still has problems with limited oral bioavailability. (en) CX-546 es un fármaco ampakina desarrollado por Cortex Pharmaceuticals, que ha sido propuesto como tratamiento para la esquizofrenia. El CX-546 era el segundo fármaco por salir de la lista del programa de investigación de Cortex, después del CX-516, sin embargo, aunque poseía mejoras respecto a su predecesora en algunos aspectos, todavía tenía problemas con su capacidad limitada de biodisponibilidad oral. (es) |
| rdfs:label |
CX-546 (en) CX-546 (es) CX-546 (fr) |
| owl:sameAs |
freebase:CX-546 yago-res:CX-546 wikidata:CX-546 dbpedia-es:CX-546 dbpedia-fr:CX-546 dbpedia-sh:CX-546 dbpedia-sr:CX-546 https://global.dbpedia.org/id/4eeWY |
| prov:wasDerivedFrom |
wikipedia-en:CX-546?oldid=1085350530&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/CX546.png |
| foaf:isPrimaryTopicOf |
wikipedia-en:CX-546 |
| is dbo:wikiPageRedirects of |
dbr:CX546 |
| is dbo:wikiPageWikiLink of |
dbr:Ampakine dbr:C14H17NO3 dbr:CX717 dbr:AMPA_receptor dbr:AMPA_receptor_positive_allosteric_modulator dbr:IDRA-21 dbr:Opioid dbr:CX546 |
| is foaf:primaryTopic of |
wikipedia-en:CX-546 |
